DUBLIN--(BUSINESS WIRE)--The "Global Metabolic Partnering 2012-2018: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
The Global Metabolic Partnering 2012-2018: Deal trends, players and financials report provides an understanding and access to the Metabolic partnering deals and agreements entered into by the worlds leading healthcare companies.
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Metabolic disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Metabolic deals.
The report presents financial deal terms values for Metabolic deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
Report scope
- Trends in Metabolic deal making in the biopharma industry since 2012
- Analysis of Metabolic deal structure
- Access to headline, upfront, milestone and royalty data
- The leading Metabolic deals by value since 2012
Available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in Metabolic dealmaking
Chapter 3 - Financial deal terms for Metabolic partnering
Chapter 4 - Leading Metabolic deals and dealmakers
Chapter 5 - Metabolic contract document directory
Chapter 6 - Metabolic dealmaking by therapeutic target
